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OBJECTIVES: Despite the number of surgical advances and innovations in techniques over time, radical
vulvectomy frequently results in substantial loss of tissue that cannot be primarily closed without tension, the
mobilization of surrounding tissues or even the rotation of myocutaneous flaps. The aim of this study was to
evaluate the feasibility of leaving the surgical vulvar open wound for secondary healing in situations where
primary closure of the vulvar wound is not possible.
METHODS: This case-control pilot study analyzed 16 women with a diagnosis of squamous cell carcinoma of the
vulva who first underwent inguinofemoral lymphadenectomy, 6-week sessions of chemotherapy and 25 daily
sessions of radiotherapy. Afterward, excision of the vulvar lesion with free margins was performed between
January 2011 and July 2017. Twelve patients underwent primary closure of the wound (control), and in
4 patients, the surgical wound was left open for secondary healing by means of a hydrofiber (case). The
inclusion criteria were a) FIGO-2009 stage II up to IIIC; b) squamous cell carcinoma; and c) no evidence of pelvic
or extrapelvic disease or pelvic nodal involvement. The exclusion criteria were extrapelvic disease or pelvic nodal
involvement, another primary cancer, or a poor clinical condition. ClinicalTrials.gov: NCT02067052.
RESULTS: The mean age of the patients at the time of the intervention was 62.1. The distribution of the stages
was as follows: II, n=6 (37 %); IIIA, n=1 (6%), IIIB, n=1 (6%) and IIIC, n=8 (51%). The mean operative time was
45 minutes. The hospital stay duration was 2 days. Full vulvar healing occurred after an average of 30 days in
the control group and after an average of 50 days in the case group.
CONCLUSION: A secondary healing strategy may be an option for the treatment of vulvar cancer in situations of
non-extensive surgical wounds when primary closure of the wound is not possible.
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’ INTRODUCTION
Vulvar cancer currently accounts for approximately 5% of
all gynecological malignancies, and the incidence is increas-
ing in developed countries (1). Currently, the mainstay of
oncological treatment for locally advanced disease is radical
vulvectomy with inguinofemoral lymphadenectomy fol-
lowed by radiotherapy and/or chemotherapy. This proce-
dure is complex and has many problems and side effects.
Disruptions in wound healing are associated with impaired
quality of life and may negatively impact prognosis because
most of these patients need to postpone adjuvant therapies
(2,3). Therefore, new approaches are necessary to improve
wound healing.
Despite the number of surgical advances and innovations
in techniques over time, radical vulvectomy frequently
results in substantial loss of tissue that cannot be primarily
closed without tension, the mobilization of surrounding
tissues or even the rotation of myocutaneous flaps (4). In fact,
a large wound size, tension on the suture line, surgery close
to contaminated areas and comorbidities, such as diabetes
and obesity, may contribute to wound breakdown (5). All of
these factors must be cautiously balanced before the primary
closure of the wound. The utility of leaving the operative
wound deliberately open for secondary healing is not well
established. This is the reason for our pilot study. This
procedure does not delay oncological treatment because our
patients always receive chemotherapy and radiotherapy at
the site of the vulva and lymph nodes at least 40 days after
lymphadenectomy, when the healing of the lymphadenec-
tomy is complete.DOI: 10.6061/clinics/2019/e1218
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The current pilot study aims to address particular situations
in which primary closure of the vulvar defect is not possible
and when the use of flaps or grafts is not advisable (risk
of contamination, severe tissue damage or the patient’s poor
clinical condition). The primary objective of this pilot study
was to evaluate the feasibility and operative outcomes of
leaving the surgical defect open for secondary healing with
the aid of a hydrofiber (6), with the outcomes including the
complication rates of the patients with locally advanced
vulvar cancer who were treated first with inguinofemoral
lymphadenectomy and chemoradiation and then with exci-
sion of the vulvar lesion with free margins.
’ METHODS
Study design
The study was conducted at Disciplina de Ginecologia,
Departamento de Obstetrícia e Ginecologia, Instituto do
Câncer do Estado de São Paulo, Faculdade de Medicina da
Universidade de São Paulo, Brazil. After ethical board review
approval (#03427312.4.0000.0065), we conducted a pilot
study with 16 cases of invasive and locally advanced vulvar
cancer. All participants have provided written informed
consent to participate in the study. This study was included
in a large protocol that enrolled patients with advanced-stage
tumors when the superficial fascia was incised, and all
palpably enlarged nodes were removed and sent for frozen
section analysis. If proven positive for metastatic spread, no
further groin dissection was undertaken. If not, a full ingu-
inofemoral lymphadenectomy was performed. Our protocol
is included at ClinicalTrials.gov: NCT02067052.
After nodal debulking of the groin, patients received
cisplatin at 40 mg/m2 once per week for 7 weeks throughout
radiotherapy, which was performed with a dose of 45-50 Gy
at 1.8 Gy/day, 5 times per week. If the lymph nodes were
compromised only superficially, radiation involved only the
inguinal drains and the primary lesion. This strategy aimed
to decrease the vulvar lesion by reducing the morbidity of
the posterior excision and to allow the rapid initiation of
chemoradiation (30 to 40 days) because the complete healing
of the femoral inguinal lymphadenectomy occurred at app-
roximately 30 days, and the patients were usually discharged
on the day following surgery.
Sixteen women with squamous cell carcinoma of the vulva
who underwent inguinofemoral lymphadenectomy followed
by chemoradiation therapy were analyzed in this study. Sur-
gical excision of the vulvar lesion with free margins followed
chemoradiation therapy. Patients were treated between
January 2011 and July 2017.
Among the 16 included patients, 12 underwent primary
closures of the surgical wound (controls). In four patients,
the vulvar surgical wound was deliberately left open for
secondary healing (cases).
Primary outcome: We evaluated whether the procedure in
the hydrofiber group (case group) resulted in a similar out-
come to that in the control group (primary tension-free
closure) for full vulvar healing. To this end, a clinical evalu-
ation was performed every 10 days. The potential confoun-
ders were clinical condition, age and body mass index (BMI),
which may influence the results.
Eligibility criteria
Inclusion criteria were a) FIGO-2009 stage II to IIIC; b)
squamous cell carcinoma; and c) no evidence of pelvic or
extrapelvic disease or pelvic nodal involvement on initial
staging by imaging (CT scan and pelvic MRI). The exclusion
criteria were extrapelvic disease, pelvic nodal involvement,
another primary cancer or a poor clinical condition for the
surgical procedure.
Clinical variables
The following preoperative information was collected
from the medical records and included: age of the patients
at diagnosis, BMI, tumor size (according to clinical examina-
tion and MRI), histological type and grade of differentiation.
Analyzed intraoperative (IO) data were as follows: operating
time and the impossibility of primary tension-free closure.
The tumor was measured using a pachometer, and data were
included in the medical files. Finally, postoperative (PO)
results, namely, the final pathology and presence of residual
disease, the duration of the hospital stay, postsurgical com-
plications and oncological follow-up, were documented.
Additionally, we included the conventional outcome para-
meters used in the evaluation of a surgical outcome, namely,
functional results, such as changes in urinary flow, vaginal
stenosis, tropism and retraction of scars; symmetry with
respect to the midline; sensory disturbances, such as pain,
dysesthesia, paresthesia, and alterations in sexual function;
and cosmetic aspects.
Procedure
The decision to leave all or part of the surgical wound
open for secondary healing was made intraoperatively based
on the absolute impossibility of primary tension-free closure
due to the extension of the vulvar defect (not larger than
4.5 cm) and/or the patient’s clinical condition and associated
comorbidities. After the resection of the vulvar tumor,
a pathologist ensured that the resected tumor margins were
free of disease. All patients were operated on by the same
surgeon. The decision to close the wound was based on the
evaluations of three surgeons.
After hospital discharge, prophylactic antibiotics were
administered for seven days. Patients, relatives and/or res-
ponsible caregivers were extensively counseled and trained
to deliver special care to the wound, including daily local
hygiene and disinfection with chlorhexidine, followed by
wound dressing with a hydrofiber dressing (a sterile dres-
sing comprising sodium carboxymethylcellulose and silver
that was 15x15 cm, used for infected wounds with moderate
to large exudation, kept moist and aided the autolytic
debridement; Aquacel AgTM, ConvaTec, Princeton, NJ, USA).
The dressing was changed three times per day (U$ 450.00 for
the entire treatment based on the USA price). Clinical control
of the wound was performed by the same examiners (the
surgeon and nurse) on a weekly basis for 10 weeks.
Visits
Control patients were followed in the same way and for
the same period. Potential bias may have been introduced
into our study by the timing of the evaluation, which
occurred every 10 days. The wounds of some patients may
have closed before the day of the evaluation.
Statistical Methods
This is a pilot study, and a power calculation was not
performed. For the statistical analysis, the mean and stan-
dard deviation of each variable was determined. We used the
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chi-square test to assess the relationships among the cate-
gorical variables mentioned above; p-values less than 0.05
were considered statistically significant. For other variables,
the unpaired Student’s t-test was used. All statistical ana-
lyses were conducted using the Statistical Package for the
Social Sciences (SPSS, SPSS Inc., Chicago, IL, US) software,
version 16.01.
’ RESULTS
Figure 1 presents the algorithm of the study. All of the
women underwent total resections of their vulvar tumors
with free margins confirmed by anatomical pathological
exams. Before surgery, five patients were excluded from the
protocol due to poor clinical conditions (Figure 1). The mean
age of the included patients at the time of the intervention
was 62.1 years (39-79), while the average BMI was 27.1 kg/m2
(19-32.5). Histology revealed invasive squamous cell vulvar
carcinoma in all cases. The distribution of the stages accor-
ding to the revised FIGO 2009 staging system for vulvar
cancer was as follows: II, n=6 (37%); IIIA, n=1 (6%), IIIB, n=1
(6%) and IIIC, n=8 (51%). The clinical features were similar
among groups, including functional results, such as changes
in urinary flow, vaginal stenosis, tropism and retraction
of scars; symmetry with respect to the midline; sensory
disturbances, such as pain, dysesthesia, paresthesia, and altera-
tions in sexual function; and cosmetic aspects (Tables 1 and 2).
No deaths related to surgery occurred. The mean operative
time was approximately 45 minutes, ranging from 30 to
55 minutes. The average hospital stay was 2 days (1 to
3 days). Two cases of wound infection (control group), 1 case
of disease progression (case group), and 4 cases of wound
breakdown (control group) were observed. Full vulvar
healing occurred after an average of 29.9 days in the control
group and after an average of 49 days in the case group
(Figure 1A-D). The two-year survival evaluation was similar
between both groups. None of the patients in the experi-
mental group had clinical conditions for myocutaneous flaps.
’ DISCUSSION
The modern concept for the treatment of advanced vulvar
cancer is radical excision of the vulvar tumor and inguino-
femoral lymphadenectomy, knowing that the optimal range
of the free margin is 8 mm. While a microscopic margin of
2 mm seems sufficient (80% of relapses occur in patients with
surgical margins less than 2 mm), less radical surgery is
associated with an increased risk of relapse (7). The condition
of the margins is the most important predictor of recurrence.
However, this process has some problems, namely, difficulties
Figure 1 - Photograph of the vulvar region of a patient with the secondary healing strategy: A. Vulvar size defect after resection
(immediately after surgery); B. Curative approach with the hydrofiber; C. Follow-up 2 weeks after surgery; D. follow-up 7 weeks after
surgery.
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in performing procedures such as the myocutaneous flap
due to sizes, localization and/or clinical conditions, such as
noncompensation diabetes and systematic arterial hyperten-
sion (8). Herein, we describe an alternative approach with a
hydrofiber for these patients. The previous chemoradiation
reduces the size of the lesion to obtain better conditions for
vulvectomy and to close the wound. However, the side effects
of this treatment (our protocol) interfere with the maintenance
of a good condition for rotating or using the local dermoipo-
dermal flaps. Therefore, the hydrofiber may be an alternative
treatment for these patients to avoid uncovered wounds.
Extension of surgery, increased age and BMI, diabetes,
smoking, prior radiotherapy with or without chemotherapy,
and local infection are important risk factors for wound
breakdown. The location of the lesion in the vulva is also a
relevant element that should be taken into account because
central and bilateral tumors are at increased risk for
postoperative dehiscence. Normally, wound infection and
breakdown following surgery become clinically evident
approximately 11 days after the procedure. Up to 58% of
patients undergoing vulvectomy suffer from complications
related to wound healing. Consequently, the radicality of the
surgery must be balanced with other risk factors to reduce
morbidity but preserve oncological safety (9). Disturbances
in these procedures may result in a poor prognosis for patients
with vulvar cancer. Therefore, if we ameliorate wound heal-
ing, the oncological prognosis can also be improved.
The prevention and treatment of wound infection and
wound breakdown in the vulva follow the general princi-
ples after surgery to the groin. Flaps, grafts and hyperbaric
oxygen therapy are additional strategies for prevention
(10,11). When the use of these strategies is not possible, such
as in patients with major comorbidities, in patients with
prior chemoradiation or in situations in which the surgical
wounds are not too extensive, the strategy of leaving the
surgical wound open for secondary healing enhanced by
the use of a hydrofiber dressing may be taken into conside-
ration. The mechanism involves decreasing the risk of
bacterial colonization and stimulating granulation tissue.
These steps also help the operative wound stay dry, speeding
re-epithelialization (6). In our study, we adopted the strategy
of leaving the surgical wound open for secondary healing in
four patients. The healing time was faster, but cicatrization
occurred. The delay to adjuvant therapy arising from the













IIB 65 17.7 60 42 39 Hypothyroidism
IIIC 46 26.1 50 41 31 Hypertension***
IIIC 59 24.5 55 40 33 Hypertension***
IIIC 76 24.8 45 42 20 Hypertension***/Diabetes Mellitus
Control group
IIB 75 25.3 41 31 33 Hypertension***
IIB 67 25.1 60 38 32 None
IIIC 39 33.3 80 39 31 Diabetes Mellitus
IIIA 79 27.5 45 28 22 Hypertension***
IIB 56 23 40 39 33 None
IIIC 50 27 41 38 30 Hypertension***
IIIC 43 34.2 50 31 32 Glaucoma
IIB 42 27.7 60 31 29 Leukemia
IIIC 77 24.5 60 39 31 Hypertension***/Diabetes Mellitus
IIB 70 17.3 41 31 35 Hypertension***/Diabetes Mellitus/CKI
IIB 72 27.7 41 39 37 Hypertension***
IIIC 77 22.5 50 39 38 Hypertension***
*Maximum diameter before chemoradiation therapy; **after chemoradiation therapy; ***systemic arterial hypertension; a p=0.93 (experimental group
versus control group, using unpaired Student’s t-test); b p= 0.26 (experimental group versus control group, using unpaired Student’s t-test); c p=0.79
experimental group versus control group, using unpaired Student’s t-test); d p=0.23 (Experimental group versus control group, using unpaired Student’s
t-test); e p=0.79 (experimental group versus control group, using unpaired Student’s t-test); f p=0.28 comparing the presence of systemic arterial
hypertension between both groups (Fisher’s exact test).
Table 2 - Functional results after surgical procedures.
Experimental group (n=4) Control group (n=12) RR (95% confidence interval) p*
Urinary flow abnormal 1 5 0.56 (0.074 to 4.21) 0.98
Pain 2 3 2.20 (0.42 to 11.47) 0.55
Dysesthesia 1 6 0.43 (0.06 to 3.29) 0.59
Paresthesia 3 8 1.36 (0.18 to 10.09) 0.99
Alteration in sexual function 3 9 1.00 (0.14 to 7.10) 1.00
No sexual activity 2 5 1.29 (0.24 to 6.99) 1.00
Vaginal stenosis 1 8 0.26 (0.03 to 1.99) 0.26
Retraction of scars 1 6 0.43 (0.06 to 3.29) 0.58
Tropism disturbance 0 1 - -
Symmetry with respect to the midline 3 5 3.00 (0.39 to 23.08) 0.57
* Fisher’s exact test; RR = Relative Risk.
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time for cicatrization was not relevant for prognosis because
all patients had received chemoradiation. Therefore, the
oncological treatment of the patients was not disrupted.
Finally, our study has some limitations because it is a pilot
study with a small number of patients. Keeping patients
from obtaining any wound protection if the wound can be
closed is unethical because of the potential for infection.
Therefore, we did not include a control without the hydro-
fiber. Additionally, the choice of closing the wound or using
the hydrofiber was based on the local conditions after the
chemoradiation treatment. The potential bias of our study
involves the evaluation that was performed every 10 days.
The wounds of some of the patients may have closed before
the day of the evaluation. The strength of our study is the
possibility of closing the wound with a hydrofiber dressing.
’ CONCLUSION
A secondary healing strategy may be an option for the
treatment of vulvar cancer in situations of nonextensive
surgical wounds when primary closure of the wound is not
possible. Further studies are needed to evaluate the use of
the hydrofiber in the routine clinical practice of the surgical
treatment of patients with vulvar cancer.
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